https://nextconsensus.com/evidence-change/ A dated, sourced record of changes in guideline, regulatory, and payer evidence, positioned on the recognition ladder (rungs 5–7). The feed is a public record, not a forecast. Tue, 14 Jul 2026 00:00:00 GMT en https://www.astrazeneca.com/media-centre/press-releases/2026/astrazeneca-licenses-novel-egfr-inhibitor.html sunvozertinib-firstline-snda-btd Tue, 14 Jul 2026 00:00:00 GMT AstraZeneca announced an exclusive global license from Dizal for sunvozertinib and confirmed that a supplemental NDA for the first-line EGFR exon 20 insertion indication has been submitted to the US FDA, which granted Breakthrough Therapy Designation in this setting. https://www.nccn.org/home/news/newsdetails?NewsId=5551 nccn-guidelines-weekly-updates Fri, 01 May 2026 00:00:00 GMT NCCN introduced a free Guidelines Weekly Updates email alongside a paid Flash Updates tier, publishing what changed across its guideline library on a fixed cadence. https://www.fda.gov/media/184871/download fda-siuu-guidance Tue, 07 Jan 2025 00:00:00 GMT FDA published its final guidance describing how firms may communicate truthful, non-misleading scientific information about unapproved uses, including requirements to keep sources unaltered, complete, and conflict-disclosed. https://icer.org/ icer-launch-price-access-report Wed, 01 Oct 2025 00:00:00 GMT ICER released its annual review of launch prices and access conditions — an independent, conflict-disclosed assessment of how new products enter coverage.